5-fluorouracil + interferon-alpha2a + interleukin-2

This is a combination regimen consisting of three agents: - **5-fluorouracil (5-FU):** A pyrimidine analog antimetabolite that inhibits thymidylate synthase, leading to disruption of DNA synthesis and cell death. It is primarily used as a chemotherapeutic agent in various solid tumors. - **Interferon-alpha2a (IFN-alpha2a):** A recombinant cytokine with immunomodulatory, antiproliferative, and antiviral properties. It enhances the immune response against tumor cells by activating natural killer cells and increasing antigen presentation. - **Interleukin-2 (IL-2):** A recombinant cytokine that stimulates proliferation and activation of T lymphocytes and natural killer cells, promoting an anti-tumor immune response. The combination has been investigated mainly for metastatic renal cell carcinoma and other advanced cancers. The rationale is to combine direct cytotoxic effects from chemotherapy with enhanced immune-mediated tumor killing from the cytokines. Clinical trials have shown modest objective response rates but also increased toxicity compared to single-agent or dual-agent regimens[1][4][6].

Other names

5-FU + IFN-alpha2a + IL-25-fluorouracil plus interferon alpha-2a plus interleukin-2